ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In announcing disappointing third-quarter results last week, Tripos disclosed that it is in "advanced discussions" with an undisclosed buyer for its Tripos Discovery Research (TDR) chemistry facility in Bude, England. The St. Louis-based informatics and drug discovery research contractor attributed an operating loss of $3.8 million largely to losses at TDR. Tripos eliminated 14 positions in Bude in August shortly after completing a major contract with Pfizer. "Throughout this year, we have dealt with the rapid realignment of the market for outsourced discovery research services to the low-cost venues in Asia and Eastern Europe," says John P. McAlister, Tripos CEO. The firm also attributes the third-quarter losses to a delay in an informatics project for Wyeth.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X